Steve Krognes

Mr. Krognes also serves on the board of directors of Guardant Health, Inc., Denali Therapeutics Inc., and Pliant Therapeutics, Inc. In September 2023, he also was appointed to the board of directors of CavystBio. He previously served on the board of directors of RLS Global AB, Corvus Pharmaceuticals, Inc. and Gritstone Bio, Inc. Mr. Krognes was the Chief Financial Officer of Denali Therapeutics Inc., from 2015 until retiring from that position in April 2022.

Mr. Krognes led successful financings for Denali Therapeutics, Inc., including its initial public offering in 2017, and contributed significantly to the company’s strategy, growth, and strong financial position. His extensive leadership experience in the biotech and pharmaceutical industries includes 12 years in total at Roche and Genentech, Inc., during which Mr. Krognes served as Chief Financial Officer of Genentech, Inc. for six years and global head of Roche’s mergers & acquisition team for six years. He also chaired the Genentech Access to Care Foundation and represented Genentech on the board and executive committee of the California Life Science Association. Before that, Mr. Krognes worked as an investment banker at Goldman Sachs, as a management consultant at McKinsey & Company, and as a venture capitalist in Scandinavia.